Tag Archives: biotechnology law

Supreme Court to Review Post-Expiration Date Royalties in Kimble v. Marvell

Posted on December 12, 2014 by Warren Woessner

Despite a negative brief from the Solicitor General’s Office, on Friday the Supreme Court granted cert. in Kimbell v. Marvell, 727 F.3d 856 (9th Cir. 2013) (a copy can be found at the end of this post). The single question … Continue reading →

Posted in Licensing | Tagged , , , , , , , , | Leave a comment

Canadian Hospital To Travel The Long And Winding Road Of “Gene Patenting”

Posted on November 3, 2014 by Warren Woessner

Arguing that human DNA is a natural product, the Children’s Hospital of Eastern Ontario (CHEO) has filed suit in Federal Court to invalidate patents claiming human DNA or diagnostic methods that use it. It has been reported that CHEO was … Continue reading →

Posted in Canadian Practice | Tagged , , , , , , , , , , | Leave a comment

Section 101 at AIPLA

Posted on October 24, 2014 by Warren Woessner

The increasingly intense conversation about patentable subject matter post-Mayo, Myriad and Alice got off to a slow start at the “Partnering for Patents” meeting held at the PTO on Wednesday. The meeting was a scattering of in-house PTO reports and … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

BIO Provides Supplemental Comments on PTO s.101 Guidelines

Posted on October 21, 2014 by Warren Woessner

BIO recently generated a letter to the PTO on the March 6th Guidelines on the patent-eligibility of subject matter in the life sciences, particularly “natural products.” BIO invited a group of in-house and private practitioners to comment on the Guidelines … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment